(3R,4S)-Tofacitinib-D3

(3R,4S)-Tofacitinib-D3 is a deuterium-labeled derivative of Tofacitinib, a Janus kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis and psoriatic arthritis. As a JAK inhibitor, (3R,4S)-Tofacitinib-D3 targets the enzymes responsible for the activation of various cytokines, which are involved in the immune response. By inhibiting JAK, (3R,4S)-Tofacitinib-D3 reduces inflammation and immune system activity, leading to the alleviation of symptoms associated with arthritis. (3R,4S)-Tofacitinib-D3 is typically used in research settings to study the pharmacokinetics and metabolism of Tofacitinib in vivo. The deuterium label allows for the tracking of the drug's distribution and transformation within the body, providing insights into its efficacy and potential side effects. Additionally, (3R,4S)-Tofacitinib-D3 can be used as a reference standard for the development and validation of analytical methods used in the quantification of Tofacitinib in biological matrices. Chemically, (3R,4S)-Tofacitinib-D3 has a molecular formula of C16H16N6O2S2D3 and a molecular weight of 392.51 g/mol. It is a white to off-white powder with a purity of at least 98% and should be stored at -20°C in a dry and dark place. Its chemical structure contains a pyrrolopyrimidine core with a substituted cyclopentane ring and a sulfonamide group. The deuterium-labeled methyl group is located at the 3-position of the cyclopentane ring.